Regentis Biomaterials announced the pricing of its initial public offering of 1,250,000 ordinary shares at an initial public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10 million before deducting underwriting discounts and estimated offering expenses payable by the company. In addition, the company has granted the underwriters a 45-day option to purchase up to an additional 187,500 Ordinary Shares to cover over-allotments, if any.
The Ordinary Shares commenced trading on the NYSE on December 4, 2025, under the symbol RGNT. The Offering is expected to close on or about December 5, 2025, subject to satisfaction of customary closing conditions.
Net proceeds will primarily support development activities, including completion of its pivotal trial and preparation of the Premarket Approval submission for GelrinC, and also for corporate purposes.
Regentis Biomaterials announced the pricing of its initial public offering of 1,250,000 ordinary shares at an initial public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10 million before deducting underwriting discounts and estimated offering expenses payable by the company. In addition, the company has granted...
Regentis Biomaterials announced the pricing of its initial public offering of 1,250,000 ordinary shares at an initial public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10 million before deducting underwriting discounts and estimated offering expenses payable by the company. In addition, the company has granted the underwriters a 45-day option to purchase up to an additional 187,500 Ordinary Shares to cover over-allotments, if any.
The Ordinary Shares commenced trading on the NYSE on December 4, 2025, under the symbol RGNT. The Offering is expected to close on or about December 5, 2025, subject to satisfaction of customary closing conditions.
Net proceeds will primarily support development activities, including completion of its pivotal trial and preparation of the Premarket Approval submission for GelrinC, and also for corporate purposes.
Copy to clipboard 
